Grant of License Option. On the terms and subject to the conditions of this Agreement, ASTI hereby grants to Allergan an option to obtain an exclusive license with respect to each ASTI Product, exercisable on a product-by-product and country-by-country basis as described in Section 2.2.
Grant of License Option. 3.01 Subject to rights of the United States under grants to UM and pursuant to 35 U.S.C. Section 201 et seq. and all implementing regulations, and subject to Section 3.02, UM grants to Company, and Company accepts, an exclusive worldwide license under Patent Rights to conduct research and development and to make, have made, use, lease, offer to sell, sell and import the Licensed Products within the Licensed Field as defined in Section 2.13 above, for the term of this Agreement. This license includes the right to grant sublicenses consistent with this Agreement.
Grant of License Option. For a period of ____ (__) days after the end of Filing Decision Period (such period, the “Option Period”), University hereby grants to XYZ a first option, without option fee other than the payments set forth in Section 4.01, (a) for XYZ and its Affiliates to acquire an exclusive, royalty bearing, worldwide license with the right to grant sublicenses, to develop, make, have made, use, offer for sale, sell and otherwise dispose of, products and methods practicing any University Invention or Joint Invention, and/or (b) for XYZ and its Affiliates to acquire a non-exclusive, royalty bearing, worldwide license with the right to grant sublicenses, to develop, make, have made, use, offer for sale, sell and otherwise dispose of, products and methods practicing University’s Background Technology (such option, the “License Option”). Upon XYZ’s request, University agrees to include into the License Option any computer software and its documentation falling under a University Copyright or Joint Copyright, if any (such computer software and documentation, collectively, the “Licensed Software”).
Grant of License Option. As consideration for Pfizer's performance of the Research Program and the payment by Pfizer to Peptide on the date of signing this Agreement of the total sum of one hundred and fifty thousand US dollars (US $150,000.00), during the term of this Agreement and for a period of six (6) months thereafter, Pfizer shall have the exclusive option to acquire an exclusive world-wide, royalty bearing, license, including the right to grant sub-licenses, to make, use, sell, offer for sale and import Products under all Peptide's right, title and interest in the Peptide Technology, Joint Technology and Joint Patent Rights in every country in the world. If Pfizer wishes to take up the option then the parties shall negotiate in good faith to reach agreement on the terms of the license which shall include the terms set forth in Exhibit C.
Grant of License Option. Voyager hereby grants to AbbVie an exclusive option, exercisable by AbbVie in its sole discretion during the License Option Period, to obtain the Exclusive License (the “License Option”).
Grant of License Option. 3.1 ARADIGM hereby grants NOVO NORDISK a world-wide sole and exclusive license under the ARADIGM Patent Rights and ARADIGM Know-How a) to use, market, distribute, sell, offer for sale, import and export the Packaged Products and the Device in and from the Territory for use within the Field, with the right to sublicense, and b) to otherwise exercise and perform its rights and obligations under this Agreement.
Grant of License Option. On the terms and subject to the ----------------------- conditions of this Agreement, Crescendo hereby grants to ALZA an option to obtain an exclusive license with respect to each Crescendo Product, exercisable on a product-by-product and country-by-country basis as described in Section 2.2.
Grant of License Option. Sutro hereby grants to BioNova or its designated Affiliate an exclusive option as described in this ARTICLE II to obtain the license grant set forth in Section 3.1 below and other related rights under this Agreement (the “License Option”).
Grant of License Option. 3.01 "Subject to rights of the United States under grants to UM and pursuant to 35 U.S.C. Section 201 et seq. and all implementing regulations, and subject to Section 3.02, UM grants to CDI, and CDI accepts, an exclusive worldwide license under Patent Rights to make, have made, use, lease, offer to sell, sell and import the Licensed Products within the Licensed Field for the term of this Agreement. This license includes the right to grant sublicenses constituent with this Agreement.
Grant of License Option. On a Designated Target-by-Designated Target basis and subject to the terms and conditions of this Agreement, Company hereby grants to Jxxxxxx the exclusive option to obtain (a) an exclusive, worldwide, royalty-bearing license, with the right to sublicense, under Company’s interest in the Joint Foreground with respect to the applicable Designated Target to make, have made, use, import, offer for sale, sell, and have sold Licensed Products in the Field (as such terms are defined in Exhibit C) and (b) a non-exclusive, worldwide, royalty-bearing license, with the right to sublicense, under any Company Background and Company Foreground with respect to the applicable Designated Target (but only to the extent such Company Background and Company Foreground are reasonably necessary to make, have made, use, import, offer for sale, sell, and have sold Licensed Products in the Field (as such terms are defined in Exhibit C)) to make, have made, use, import, offer for sale, sell, and have sold Licensed Products in the Field (the “License”) pursuant to a written agreement (the “License Agreement”) on mutually agreed terms and conditions, including the terms set forth on Exhibit C (such option, the “License Option”). For clarification, nothing in this Agreement shall prevent Company from negotiating or completing any transaction for the sale of all or substantially all of the business or assets of Company, whether by merger, sale of stock, sale of assets or otherwise; provided, that any successor to Company in such transaction shall remain subject to the License Option during the License Option Term. Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.
